Frank Kalkbrenner

Frank is Managing Director of the Boehringer Ingelheim Corporate Venture Fund. Over the last three years, he has been involved in several investments of the fund. He serves as board member of Hookipa Biotech in Vienna, STAT Diagnostica in Barcelona, Eyevensys in Paris and Acousia Therapeutics in Tuebingen. In addition, he is member of the supervisory and the advisory board of Inserm Transfer Initiative a French Seed Investment Fund based in Paris.

Frank studied medicine and holds a degree in Pharmacology and Toxicology. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of Pharmacology of the Freie Universität, Berlin. His academic research focused on gene regulation and signal transduction mediated by ion channels and G proteins.
In 1997 he began his industrial career by joining Schering AG as senior scientist in Experimental Dermatology. In 1999 Frank joined Boehringer Ingelheim and held several positions in the department of Pulmonary Research. In 2005 he took over the responsibility for the Licensing Department. In this function, he was responsible for the licensing activities of the German Boehringer Ingelheim organization as well as for competitive assessment and scientific information systems. In addition, he built up the NBE Research unit at the German Research site in Biberach. In 2010 - shortly after its start - Frank joined the Boehringer Ingelheim Venture Fund.

Dr. Frank Kalkbrenner

Frank Kalkbrenner

Contact Venture Fund